MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
KEYNOTE-189 Data Presentation: KEYTRUDA® (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic, non-squamous NSCLC
NSCLC /
KEYTRUDA /
Training and Resources /
Root /

KEYNOTE-189 Data Presentation: KEYTRUDA® (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic, non-squamous NSCLC

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Download our KEYNOTE-189 slide deck that discusses KEYTRUDA + plat-pem clinical data in metastatic non-squamous untreated NSCLC in adults whose tumours have no EGFR- or ALK-positive mutations.

Find out more information about KEYTRUDA in metastatic NSCLC:

Click Here
download

PDF, 3.59 MB

Register with MSD Connect

  • Sign up for events
  • Complete learning modules
  • Receive cancer resources
  • Access additional content
Register →

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01114 | Date of Preparation: July 2020